Q1 FY25 saw year-over-year growth in both revenue and net profit on a standalone and consolidated basis, with regulatory income significantly boosting results. New subsidiaries were added, and key board appointments were made, while regulatory and legal uncertainties remain.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.